Korean J Pain.  2018 Oct;31(4):235-243. 10.3344/kjp.2018.31.4.235.

Modalities in managing postherpetic neuralgia

Affiliations
  • 1The First Affiliated Hospital of Chongqing Medical University, Chongqing Shi, China. 3034203217@qq.com

Abstract

Postherpetic neuralgia (PHN) is the most troublesome side effect of Herpes Zoster (HZ), which mainly affects the elderly and immunocompromised populations. Despite the current advancement of treatments, PHN persists in many individuals influencing their daily activities and reducing their quality of life. Anticonvulsants, antidepressants, topical therapies including lidocaine and capsaicin, and opioids, are the most widely used therapies for the treatment of PHN. These medications come with their adverse effects, so they should be used carefully with the elderly or with patients with significant comorbidities. Other measures like botulinum toxin, nerve blocks, spinal cord stimulation, and radiofrequency have also contributed significantly to the management of PHN. However, the efficacy, safety, and tolerability of these invasive methods need to be carefully monitored when administering them. Early diagnosis and early initiation of treatment can reduce the burden associated with PHN. The zoster vaccine has effectively reduced the incidence of HZ and PHN. In this article, we discuss the treatment options available for the management of PHN, mainly focusing on the efficacy and safety of different therapeutic modalities.

Keyword

Aged; Anticonvulsants; Antidepressants; Botulinum toxin; Capsaicin; Herpes zoster vaccination; Incidence; Nerve block; Opioids; Postherpetic neuralgia; Quality of life; Spinal cord stimulation

MeSH Terms

Aged
Analgesics, Opioid
Anticonvulsants
Antidepressive Agents
Botulinum Toxins
Capsaicin
Comorbidity
Early Diagnosis
Herpes Zoster
Herpes Zoster Vaccine
Humans
Incidence
Lidocaine
Nerve Block
Neuralgia, Postherpetic*
Quality of Life
Spinal Cord Stimulation
Analgesics, Opioid
Anticonvulsants
Antidepressive Agents
Botulinum Toxins
Capsaicin
Herpes Zoster Vaccine
Lidocaine

Cited by  2 articles

Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia
Grisuna Singh, Sejin Song, Eunjoo Choi, Pyung-Bok Lee, Francis Sahngun Nahm
Korean J Pain. 2020;33(3):201-207.    doi: 10.3344/kjp.2020.33.3.201.

Prevention, diagnosis, and treatment of opioid use disorder under the supervision of opioid stewardship programs: it’s time to act now
Eun-Ji Kim, Eun-Jung Hwang, Yeong-Min Yoo, Kyung-Hoon Kim
Korean J Pain. 2022;35(4):361-382.    doi: 10.3344/kjp.2022.35.4.361.


Reference

1. Gan EY, Tian EA, Tey HL. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol. 2013; 14:77–85. PMID: 23456596.
Article
2. Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014; 7:125–132. PMID: 24648752.
Article
3. Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc. 2016; 9:447–454. PMID: 27703368.
Article
4. Nalamachu S, Morley-Forster P. Diagnosing and managing postherpetic neuralgia. Drugs Aging. 2012; 29:863–869. PMID: 23038608.
Article
5. Khadem T, Stevens V. Therapeutic options for the treatment of postherpetic neuralgia: a systematic review. J Pain Palliat Care Pharmacother. 2013; 27:268–283. PMID: 23901906.
Article
6. Hadley GR, Gayle JA, Ripoll J, Jones MR, Argoff CE, Kaye RJ, et al. Post-herpetic neuralgia: a review. Curr Pain Headache Rep. 2016; 20:17. PMID: 26879875.
Article
7. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014; 4:e004833.
Article
8. Chen LK, Arai H, Chen LY, Chou MY, Djauzi S, Dong B, et al. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific. BMC Infect Dis. 2017; 17:213. PMID: 28298208.
Article
9. Werner RN, Nikkels AF, Marinović B, Schäfer M, Czarnecka-Operacz M, Agius AM, et al. European consensus-based (S2k) guideline on the management of herpes zoster-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: diagnosis. J Eur Acad Dermatol Venereol. 2017; 31:9–19. PMID: 27804172.
Article
10. Jeon YH. Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain. 2015; 28:177–184. PMID: 26175877.
Article
11. Bader MS. Herpes zoster: diagnostic, therapeutic, and preventive approaches. Postgrad Med. 2013; 125:78–91.
Article
12. Johnson RW, Rice AS. Postherpetic neuralgia. N Engl J Med. 2014; 371:1526–1533. PMID: 25317872.
Article
13. Schmader K. Herpes zoster. Clin Geriatr Med. 2016; 32:539–553. PMID: 27394022.
Article
14. Haanpää M, Rice AS, Rowbotham MC. Treating herpes zoster and postherpetic neuralgia. Pain Clin Updates. 2015; 23:1–8. Available at https://s3.amazonaws.com/rdcmsiasp/files/production/public/Content/ContentFolders/Publications2/PainClinicalUpdates/Archives/pcu_vol23_no4_may2015.pdf.
15. Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). Lancet. 1962; 1:839–840.
Article
16. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009; CD007076. PMID: 19588419.
Article
17. Pfizer. Neurontin 2017 [Internet]. New York, NY: Division of Pfizer Inc.;2017. cited 2017 Oct 17. Available at http://labeling.pfizer.com/ShowLabeling.aspx?id=630.
18. Meng FY, Zhang LC, Liu Y, Pan LH, Zhu M, Li CL, et al. Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials. Minerva Anestesiol. 2014; 80:556–567. PMID: 24257149.
19. Depomed. Gralise 2012 [Internet]. Newark, NJ: Depomed, Inc.;2012. cited 2017 Oct 17. Available at https://www.gralise.com/sites/default/files/GRALISE_PI_DEC2012.pdf.
20. Sang CN, Sathyanarayana R, Sweeney M. DM-1796 Study Investigators. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clin J Pain. 2013; 29:281–288. PMID: 22801243.
Article
21. Arbor. Horizant 2016 [Internet]. Atlanta, GA: Arobor Pharmaceuticals, LLC;2016. cited 2017 Oct 17. Available at https://www.horizant.com/assets/docs/Horizant_PrescribingInformation.pdf.
22. Lal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, Cundy KC. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. J Clin Pharmacol. 2013; 53:29–40. PMID: 23400741.
Article
23. Pfizer. Lyrica 2016 [Internet]. New York, NY: Division of Pfizer Inc.;2016. cited 2017 Oct 17. Available at http://labeling.pfizer.com/showlabeling.aspx?id=561.
24. Ifuku M, Iseki M, Hidaka I, Morita Y, Komatus S, Inada E. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. Pain Med. 2011; 12:1112–1116. PMID: 21692969.
Article
25. Zilliox LA. Neuropathic pain. Continuum (Minneap Minn). 2017; 23:512–532. PMID: 28375916.
Article
26. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005; 2:e164. PMID: 16013891.
Article
27. Enamandram M, Rathmell JP, Kimball AB. Chronic pain management in dermatology: a guide to assessment and nonopioid pharmacotherapy. J Am Acad Dermatol. 2015; 73:563–573. PMID: 26369840.
28. Harden RN, Kaye AD, Kintanar T, Argoff CE. Evidence-based guidance for the management of postherpetic neuralgia in primary care. Postgrad Med. 2013; 125:191–202.
Article
29. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014; CD010958. PMID: 25058164.
Article
30. Grunenthal. Versatis 2015 [Internet]. Buckinghamshire: Grunenthal Ltd.;2015. cited 2017 Oct 17. Available at http://www.medicines.org.uk/emc/medicine/19291/SPC/Versatis%2b5%2b%2bMedicated%2bPlaster/.
31. Krumova EK, Zeller M, Westermann A, Maier C. Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers. Pain. 2012; 153:273–280. PMID: 21995882.
Article
32. Campbell BJ, Rowbotham M, Davies PS, Jacob P 3rd, Benowitz NL. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002; 91:1343–1350. PMID: 11977110.
Article
33. Navez ML, Monella C, Bösl I, Sommer D, Delorme C. 5% lidocaine medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability. Pain Ther. 2015; 4:1–15. PMID: 25896574.
Article
34. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009; 25:1663–1676. PMID: 19485723.
Article
35. Baranidharan G, Das S, Bhaskar A. A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain. Ther Adv Neurol Disorder. 2013; 6:287–297.
Article
36. Irving GA, Backonja MM, Dunteman E, Blonsky ER, Vanhove GF, Lu SP, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011; 12:99–109. PMID: 21087403.
Article
37. Acorda. Qutenza 2013 [Internet]. Ardsley, NY: Acorda Therapeutics, Inc.;2013. cited 2017 Oct 17. Available at http://www.qutenza.com/_docs/qutenza_full_PI_.pdf.
38. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017; CD007393. PMID: 28085183.
Article
39. Burness CB, McCormack PL. Capsaicin 8 % patch: a review in peripheral neuropathic pain. Drugs. 2016; 76:123–134. PMID: 26666418.
Article
40. Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002; 59:1015–1021. PMID: 12370455.
Article
41. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003; 104:323–331. PMID: 12855342.
Article
42. Shackleton T, Ram S, Black M, Ryder J, Clark GT, Enciso R. The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016; 122:61–71. PMID: 27260275.
Article
43. Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel). 2017; 9:pii: E260.
Article
44. Ding XD, Zhong J, Liu YP, Chen HX. Botulinum as a toxin for treating post-herpetic neuralgia. Iran J Public Health. 2017; 46:608–611. PMID: 28560190.
45. Kim HJ, Ahn HS, Lee JY, Choi SS, Cheong YS, Kwon K, et al. Effects of applying nerve blocks to prevent postherpetic neuralgia in patients with acute herpes zoster: a systematic review and meta-analysis. Korean J Pain. 2017; 30:3–17. PMID: 28119767.
Article
46. Ing MR, Hellreich PD, Johnson DW, Chen JJ. Transcutaneous electrical nerve stimulation for chronic post-herpetic neuralgia. Int J Dermatol. 2015; 54:476–480. PMID: 25600258.
Article
47. Lerman IR, Chen JL, Hiller D, Souzdalnitski D, Sheean G, Wallace M, et al. Novel high-frequency peripheral nerve stimulator treatment of refractory postherpetic neuralgia: a brief technical note. Neuromodulation. 2015; 18:487–493. PMID: 25832898.
Article
48. Kim K, Jo D, Kim E. Pulsed radiofrequency to the dorsal root ganglion in acute herpes zoster and postherpetic neuralgia. Pain Physician. 2017; 20:E411–E418. PMID: 28339440.
49. Kim ED, Lee YI, Park HJ. Comparison of efficacy of continuous epidural block and pulsed radiofrequency to the dorsal root ganglion for management of pain persisting beyond the acute phase of herpes zoster. PLoS One. 2017; 12:e0183559. PMID: 28827823.
Article
50. Shi Y, Wu W. Treatment of neuropathic pain using pulsed radiofrequency: a meta-analysis. Pain Physician. 2016; 19:429–444. PMID: 27676660.
51. Yanamoto F, Murakawa K. The effects of temporary spinal cord stimulation (or spinal nerve root stimulation) on the management of early postherpetic neuralgia from one to six months of its onset. Neuromodulation. 2012; 15:151–154. PMID: 22376181.
Article
52. Ko YK, Lee HY, Lee WY. Clinical experiences on the effect of scrambler therapy for patients with postherpetic neuralgia. Korean J Pain. 2013; 26:98–101. PMID: 23342218.
Article
53. Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ. Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manage. 2012; 43:87–95. PMID: 21763099.
Article
54. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008; 57:1–30.
55. Merck. Zostavax 2017 [Internet]. Kenilworth: Merck Sharp & Dohme Corp.;2017. cited 2017 Oct 17. Available at http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf.
56. Kang DH, Kim SY, Kim HG, Park JH, Kim TK, Kim KH. Earlier treatment improves the chances of complete relief from postherpetic neuralgia. Korean J Pain. 2017; 30:214–219. PMID: 28757922.
Article
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr